Novo Nordisk
NVO
#14
Rank
$572.92 B
Marketcap
$128.40
Share price
0.27%
Change (1 day)
65.34%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

P/E ratio for Novo Nordisk (NVO)

P/E ratio as of March 2024 (TTM): 45.0

According to Novo Nordisk's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 44.9618. At the end of 2022 the company had a P/E ratio of 31.2.

P/E ratio history for Novo Nordisk from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202231.210.85%
202128.139.33%
202020.25.1%
201919.227.78%
201815.0-18.22%
201718.414.18%
201616.1-31.15%
201523.420.48%
201419.410.09%
201317.659.01%
201211.1-32.22%
201116.4-18.47%
201020.130.58%
200915.436.79%
200811.2-50.9%
200722.920.28%
200619.018.28%
200516.1-0.43%
200416.116.66%
200313.83.55%
200213.4-22.51%
200117.2

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
14.9-66.82%๐Ÿ‡บ๐Ÿ‡ธ USA
143 218.69%๐Ÿ‡บ๐Ÿ‡ธ USA
15.3-66.01%๐Ÿ‡ซ๐Ÿ‡ท France
13.7-69.62%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.